Paul G. Richardson

Paul G. Richardson

Hematology Oncology | Oncology | Hematology
450 Brookline Avenue
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 660 publications

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.

Journal: The New England journal of medicine
Published: July 15, 2026

Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma.

Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma.

Journal: Leukemia
Published: May 09, 2026

Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myeloma.

Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myeloma.

Journal: Haematologica
Published: May 08, 2026

The application of fluorinated α-amino acids to drug discovery techniques.

The application of fluorinated α-amino acids to drug discovery techniques.

Journal: Expert opinion on drug discovery
Published: May 06, 2026

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Journal: Lancet (London, England)
Published: April 29, 2026

Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma.

Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma.

Journal: Expert opinion on investigational drugs
Published: April 23, 2026

A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).

A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).

Journal: Expert opinion on biological therapy
Published: March 17, 2026

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Journal: Nature medicine
Published: March 13, 2026

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

Journal: Haematologica
Published: March 13, 2026

The HPTN 094 Peer Navigation Model: Integration of Substance Use Treatment and HIV Prevention and Care for People Who Inject Drugs.

The HPTN 094 Peer Navigation Model: Integration of Substance Use Treatment and HIV Prevention and Care for People Who Inject Drugs.

Journal: Journal of addiction medicine
Published: February 26, 2026

Phase IIB, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID-19.

Phase IIB, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID-19.

Journal: European journal of haematology
Published: February 26, 2026

Editorial Expression of Concern: Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

Editorial Expression of Concern: Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

Journal: Nature medicine
Published: February 25, 2026
Showing 1-12 of 660

Last Updated: 09/26/2026